Cancer patients with autoimmune diseases may still be eligible for immunotherapy, but treatment requires careful evaluation. Immune checkpoint inhibitors can help the immune system attack cancer cells, yet they may also trigger autoimmune flare-ups or other inflammatory complications. Research is helping doctors understand which patients can benefit and how to manage these risks safely.
Understanding Immunotherapy in Patients With Autoimmune Diseases
Immunotherapy has transformed cancer treatment by helping the immune system recognize and attack malignant cells. Immune checkpoint inhibitors, in particular, have improved outcomes for some patients with advanced melanoma, lung cancer, kidney cancer, bladder cancer, and other malignancies.
However, using these medications in patients with existing autoimmune diseases presents additional challenges.
Autoimmune diseases develop when the immune system mistakenly attacks healthy tissues. Conditions such as rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease involve abnormal immune responses that may already require medication to control inflammation.
Because immunotherapy can increase immune activity, doctors must consider whether treatment could worsen an existing autoimmune condition.
Historically, many clinical trials excluded patients with autoimmune diseases because researchers were concerned about potentially severe immune-related complications. This exclusion created gaps in medical knowledge about the safety and effectiveness of immunotherapy in this population.
As research expands, healthcare professionals are developing a better understanding of when immunotherapy may be appropriate and how treatment risks can be managed.
Why Have Patients With Autoimmune Diseases Been Excluded From Immunotherapy Trials?
Clinical trials are designed to evaluate whether a treatment is safe and effective under carefully controlled conditions.
When immune checkpoint inhibitors were first being studied, researchers frequently excluded patients with active autoimmune diseases or those receiving significant immunosuppressive treatment.
The primary concern was that stimulating the immune system could worsen an existing autoimmune condition.
For example, a patient with rheumatoid arthritis might experience increased joint inflammation, while someone with inflammatory bowel disease could develop worsening gastrointestinal symptoms.
Researchers were also concerned that medications used to control autoimmune diseases, such as corticosteroids and other immunosuppressants, might influence the effectiveness of cancer immunotherapy.
How Exclusion From Clinical Trials Created Treatment Challenges
Although these restrictions helped protect participants during early clinical research, they also limited the evidence available to doctors treating patients with both conditions.
Without sufficient clinical trial data, oncologists faced difficult questions:
- Could immunotherapy safely treat cancer in patients with autoimmune diseases?
- Would existing autoimmune symptoms become more severe?
- Could immunosuppressive medications interfere with cancer treatment?
- Would patients with autoimmune diseases experience the same cancer treatment benefits as other patients?
- How should doctors manage autoimmune flare-ups during immunotherapy?
These uncertainties made treatment decisions particularly complicated for patients with advanced cancers who might otherwise benefit from immune checkpoint inhibitors.
How Immune Checkpoint Inhibitors Work
The immune system uses specialized cells, including T cells, to identify and respond to abnormal or infected cells.
However, the immune system also contains regulatory mechanisms that prevent excessive inflammation and protect healthy tissues.
Some of these mechanisms are called immune checkpoints.
Cancer cells can exploit these checkpoints to avoid detection or destruction by immune cells.
Immune checkpoint inhibitors are medications designed to block certain inhibitory signals, allowing T cells to respond more effectively against cancer.
Common Types of Immune Checkpoint Inhibitors
Several checkpoint pathways are targeted in cancer treatment.
PD-1 inhibitors: Medications such as nivolumab and pembrolizumab block the programmed cell death protein 1 pathway, helping restore T-cell activity against cancer cells.
PD-L1 inhibitors: These medications block a protein that some cancer cells use to suppress immune responses.
CTLA-4 inhibitors: Medications such as ipilimumab target another checkpoint involved in regulating T-cell activation.
These therapies can produce meaningful and sometimes long-lasting responses in certain cancers.
However, increasing immune activity may also cause the immune system to attack healthy organs and tissues.
This is particularly important for patients who already have autoimmune disorders.
Why Immunotherapy May Trigger Autoimmune Flare-Ups
Autoimmune diseases involve immune responses directed against the body’s own tissues.
Immune checkpoint inhibitors remove some of the regulatory signals that normally limit immune activity.
Although this can improve the immune system’s ability to attack cancer cells, it may also increase inflammation elsewhere in the body.
For patients with preexisting autoimmune conditions, treatment can sometimes trigger a flare-up of their underlying disease.
A flare occurs when symptoms of an autoimmune condition become more active or severe.
Examples of Possible Autoimmune Complications
The type of complication depends partly on the patient’s underlying condition.
- Rheumatoid arthritis: Increased joint pain, swelling, and stiffness
- Lupus: Worsening inflammatory symptoms affecting the skin, joints, kidneys, or other organs
- Inflammatory bowel disease: Increased diarrhea, abdominal pain, or intestinal inflammation
- Multiple sclerosis: Potential worsening of neurological symptoms
- Systemic sclerosis: Possible worsening of inflammatory or organ-related complications
Checkpoint inhibitors can also cause new immune-related adverse events unrelated to the patient’s original autoimmune diagnosis.
These may include inflammation of the colon, lungs, liver, thyroid, skin, or other organs.
The severity varies considerably. Some reactions are mild and manageable, while others can become serious or life-threatening.
Not every patient with an autoimmune disease experiences these complications.
The NCI-Sponsored Clinical Trial Investigating Immunotherapy Safety
In 2019, the National Cancer Institute highlighted a clinical trial designed to investigate immunotherapy in patients diagnosed with both advanced cancer and autoimmune diseases.
The study represented an important effort to address the limited evidence available for this patient population.
Researchers sought to understand whether immune checkpoint inhibitors could provide meaningful cancer treatment benefits without causing unacceptable autoimmune complications.
What Were the Objectives of the Clinical Trial?
The study was designed to evaluate several important questions:
- How frequently do autoimmune flare-ups occur during immunotherapy?
- How severe are these flare-ups?
- Can patients continue immunotherapy after developing autoimmune symptoms?
- How effectively does treatment control cancer?
- Which patient characteristics may influence treatment safety?
- How do autoimmune medications affect treatment outcomes?
The trial also aimed to improve researchers’ understanding of the relationship between cancer immunity and autoimmune disease.
Which Patients Were Included?
The original study plan involved patients with advanced cancer and a range of autoimmune conditions.
These included:
- Rheumatoid arthritis
- Systemic lupus erythematosus
- Multiple sclerosis
- Sjögren syndrome
- Systemic sclerosis
- Dermatomyositis
- Inflammatory bowel disease
- Crohn’s disease
The research focused on patients whose cancer treatment options could include immune checkpoint inhibition.
Which Immunotherapy Drug Was Studied?
The trial investigated nivolumab, marketed as Opdivo.
Nivolumab is a PD-1 immune checkpoint inhibitor used in the treatment of several malignancies.
By blocking the PD-1 pathway, nivolumab can help immune cells recognize and attack cancer cells.
Researchers planned to monitor autoimmune symptoms, treatment-related adverse events, tumor responses, and survival outcomes.
The original trial announcement was an important development, but its planned enrollment and objectives should not be mistaken for completed clinical results.
What Research Suggests About Immunotherapy and Autoimmune Diseases
Clinical experience and observational research have provided additional information about immunotherapy in patients with preexisting autoimmune conditions.
Studies suggest that some patients with autoimmune diseases can receive immune checkpoint inhibitors and experience meaningful cancer treatment responses.
However, these patients may face a higher risk of autoimmune flare-ups or immune-related adverse events compared with patients without autoimmune disease.
Can Immunotherapy Still Be Effective?
Yes. Having an autoimmune disease does not automatically prevent a patient from responding to cancer immunotherapy.
Some observational studies have reported tumor responses among patients with preexisting autoimmune conditions.
However, outcomes differ depending on cancer type, the specific checkpoint inhibitor, autoimmune disease activity, and other clinical factors.
The available evidence does not establish that immunotherapy is equally safe or equally effective for every autoimmune condition.
Are Autoimmune Side Effects Always Severe?
No. Some patients experience mild or moderate autoimmune flare-ups that can be managed with medication or temporary treatment adjustments.
Others may develop more serious complications requiring hospitalization, immunosuppressive treatment, or permanent discontinuation of immunotherapy.
Patients with active or poorly controlled autoimmune disease may face different risks from those whose conditions have remained stable.
Certain neurological, cardiac, and other organ-threatening autoimmune disorders require particularly careful evaluation.
How Doctors Determine Whether Immunotherapy Is Appropriate
Choosing immunotherapy for a patient with an autoimmune disease requires an individualized assessment.
An oncologist may work with a rheumatologist, neurologist, gastroenterologist, or another specialist depending on the underlying condition.
Factors That Influence Treatment Decisions
Cancer type and stage: Immunotherapy is more effective for some cancers than others. Treatment selection depends on the diagnosis and available evidence.
Autoimmune disease activity: Patients with stable, well-controlled autoimmune diseases may have different risks from those experiencing active inflammation.
Previous autoimmune complications: A history of severe organ involvement may influence whether checkpoint inhibitors are appropriate.
Current medications: Corticosteroids and other immunosuppressive drugs may affect treatment planning and require careful management.
Available cancer treatments: Doctors consider whether other effective therapies are available and how their potential benefits and risks compare.
Patient preferences: Treatment decisions should incorporate the patient’s goals, concerns, and willingness to accept possible complications.
There is no universal recommendation that all patients with autoimmune diseases should receive or avoid immunotherapy.
The decision depends on the individual’s medical circumstances.
Managing Autoimmune Symptoms During Cancer Immunotherapy
Careful monitoring is essential when immune checkpoint inhibitors are used in patients with autoimmune diseases.
Healthcare teams may establish baseline assessments before treatment begins to document existing symptoms and organ function.
These assessments help distinguish preexisting autoimmune activity from new treatment-related complications.
Monitoring During Treatment
Depending on the patient’s condition, monitoring may involve:
- Regular evaluation of autoimmune symptoms
- Blood tests to assess liver, kidney, or thyroid function
- Monitoring for gastrointestinal inflammation
- Assessment of respiratory or neurological changes
- Coordination with autoimmune disease specialists
- Reviewing medications and treatment-related side effects
Patients should report new or worsening symptoms promptly rather than waiting until their next scheduled appointment.
What Happens if an Autoimmune Flare Occurs?
Management depends on the affected organ and severity of symptoms.
Mild complications may be managed with close monitoring and appropriate medications.
More significant reactions may require corticosteroids, additional immunosuppressive treatment, or temporarily withholding immunotherapy.
Severe immune-related adverse events may require permanent discontinuation of the checkpoint inhibitor.
Patients should not independently stop prescribed autoimmune medications or cancer treatments without medical guidance.
The Role of Supportive Care During Immunotherapy
Patients managing both cancer and autoimmune disease may experience fatigue, pain, sleep disturbances, nutritional challenges, and emotional stress.
Supportive care can help address these concerns while medical teams monitor cancer treatment and autoimmune activity.
Nutrition and Physical Well-Being
Adequate nutrition supports normal physiological function and helps patients maintain strength during treatment.
Nutritional recommendations should account for the patient’s cancer diagnosis, autoimmune condition, medications, and gastrointestinal symptoms.
For example, patients with inflammatory bowel disease may require dietary adjustments during periods of active intestinal inflammation.
Managing Fatigue and Stress
Fatigue can result from cancer, autoimmune inflammation, treatment side effects, anemia, or sleep disturbances.
Gentle physical activity, appropriate rest, psychological support, and symptom-directed treatment may improve daily functioning.
Stress-management practices can support emotional well-being, but they should not be presented as treatments that control cancer or autoimmune disease activity.
Complementary Therapies and Safety
Some patients explore complementary approaches such as acupuncture, massage, meditation, or nutritional supplements.
These interventions should be discussed with the healthcare team before use.
Certain supplements and herbal products may interact with cancer medications or immunosuppressive therapies.
An integrative approach should prioritize coordination, safety, symptom management, and evidence-based treatment decisions.
The Future of Immunotherapy for Patients With Autoimmune Diseases
Research involving patients with both cancer and autoimmune conditions continues to address important gaps in clinical knowledge.
Scientists are investigating which patients may benefit most from checkpoint inhibitors, how to predict autoimmune complications, and whether specific treatment strategies can reduce adverse events.
Future research may also clarify how different autoimmune diseases influence cancer treatment responses.
More inclusive clinical trials could help physicians make better-informed decisions for patients who were historically underrepresented in cancer research.
However, improved understanding does not mean immunotherapy will become appropriate for every patient with an autoimmune disease.
Treatment will continue to require individualized evaluation of potential benefits and risks.
The Bottom Line
Immunotherapy may be an option for some cancer patients with preexisting autoimmune diseases, but treatment requires careful medical assessment.
Immune checkpoint inhibitors can help the immune system recognize and attack cancer cells. At the same time, they may worsen existing autoimmune conditions or cause new inflammatory complications.
Research, including the NCI-sponsored trial highlighted in 2019, has helped draw attention to the need for better evidence in this patient population.
The most appropriate treatment strategy depends on cancer characteristics, autoimmune disease activity, medical history, and the patient’s overall condition.
Close coordination between oncology and autoimmune disease specialists is essential for evaluating treatment suitability and managing potential complications.
FAQs
Can cancer patients with autoimmune diseases receive immunotherapy?
Yes. Some patients with autoimmune diseases may be eligible for immunotherapy, particularly when their autoimmune condition is stable or well controlled. Eligibility depends on cancer type, autoimmune disease severity, treatment history, and the potential benefits and risks of therapy.
Is immunotherapy safe for patients with rheumatoid arthritis?
Some patients with rheumatoid arthritis can receive immune checkpoint inhibitors, but treatment may trigger increased joint inflammation or other immune-related side effects. Oncologists and rheumatologists should evaluate disease activity and develop an appropriate monitoring plan.
Can immunotherapy make lupus worse?
Yes. Immunotherapy may trigger lupus flare-ups or other inflammatory complications in some patients. The risk varies according to disease activity, organ involvement, and treatment characteristics. Patients with lupus require individualized evaluation before receiving immune checkpoint inhibitors.
Why were patients with autoimmune diseases excluded from immunotherapy trials?
Many early clinical trials excluded these patients because immune checkpoint inhibitors can increase immune activity and potentially worsen autoimmune conditions. Researchers also wanted to minimize complications that could make treatment safety difficult to evaluate.
What is nivolumab, and how does it work?
Nivolumab, marketed as Opdivo, is an immune checkpoint inhibitor that blocks the PD-1 pathway. This helps certain immune cells recognize and attack cancer cells. It is approved for several cancer types but may cause immune-related adverse events.
Does having an autoimmune disease reduce the effectiveness of immunotherapy?
Not necessarily. Some patients with autoimmune diseases respond to checkpoint inhibitors. However, treatment effectiveness varies, and factors such as autoimmune disease activity, immunosuppressive medications, and cancer characteristics may influence outcomes.
What happens if an autoimmune flare occurs during immunotherapy?
Doctors may recommend monitoring, corticosteroids, other immunosuppressive medications, or temporarily withholding immunotherapy. Severe complications may require permanent treatment discontinuation. Management depends on the affected organ and symptom severity.
Can patients taking immunosuppressive medications receive cancer immunotherapy?
Some may be eligible, but the decision requires careful evaluation. Immunosuppressive medications can influence treatment planning, and their effects vary depending on the drug, dose, and underlying condition. Patients should never change these medications without medical guidance.
Are all types of immunotherapy equally risky for patients with autoimmune diseases?
No. Immunotherapy includes several treatment categories with different mechanisms and safety profiles. Risks associated with immune checkpoint inhibitors should not automatically be applied to every immunotherapy approach.
Should patients with autoimmune diseases avoid immunotherapy completely?
No. An autoimmune diagnosis does not automatically rule out immunotherapy. Patients should discuss the potential benefits, risks, and available alternatives with their oncology team and the specialists managing their autoimmune condition.